## **Quarterly Portfolio Disclosure**

As of December 31, 2023

## **Summary of Investment Portfolio**

PORTFOLIO ALLOCATION	% OF NAV
Equities	99.4
Other assets (liabilities)	0.4
Exchange-traded funds	0.3
Cash and cash equivalents	(0.1)
REGIONAL ALLOCATION	% OF NAV

	70 <b>01</b> 1010
United States	71.7
Switzerland	6.5
Denmark	5.8
Japan	5.3
United Kingdom	5.1
France	2.5
Australia	1.7
Italy	0.7
Other assets (liabilities)	0.4
Germany	0.2
Sweden	0.2
Cash and cash equivalents	(0.1)

SECTOR ALLOCATION	% OF NAV
Pharmaceuticals	41.9
Health care providers and services	17.6
Health care equipment and supplies	17.2
Biotechnology	13.7
Life sciences tools and services	8.0
Commercial services and supplies	1.0
Other assets (liabilities)	0.4
Exchange-traded funds	0.3
Cash and cash equivalents	(0.1)

TOP 25 POSITIONS	% OF NAV
lssuer	
UnitedHealth Group Inc.	6.3
Eli Lilly and Co.	5.7
Novo Nordisk AS	5.6
Johnson & Johnson	5.2
AbbVie Inc.	4.7
Novartis AG	3.8
Amgen Inc.	3.1
Merck & Co. Inc.	3.0
Thermo Fisher Scientific Inc.	2.8
CVS Health Corp.	2.5
Elevance Health Inc.	2.4
Roche Holding AG	2.4
Gilead Sciences Inc.	2.4
Stryker Corp.	2.4
Cigna Corp.	2.3
AstraZeneca PLC	2.1
GSK PLC	2.0
Abbott Laboratories	1.8
EssilorLuxottica	1.8
IQVIA Holdings Inc.	1.6
Agilent Technologies Inc.	1.6
Medtronic PLC	1.6
Pfizer Inc.	1.5
GE HealthCare Technologies Inc.	1.5
Centene Corp.	1.5
Top long positions as a percentage	
of total net asset value	71.6
Total net asset value of the Fund	\$308.7 million

The Fund held no short positions at the end of the period.

The investments and percentages may have changed since December 31, 2023, due to the ongoing portfolio transactions of the Fund. Quarterly updates of holdings are available within 60 days of the end of each quarter except for March 31, the Fund's fiscal year-end, when they are available within 90 days.

